

DAVID SACERDOTI

Born: March 20, 1956 - Padova, Italy

EDUCATION:

University of Padova, Italy, Doctor of Medicine (Laurea)	1974-1980
University of Padova, Italy, School of Specialization in Internal Medicine, Specialist in Internal Medicine	1980-1985
University of Padova, Italy, School of Specialization in Cardiology, Specialist in Cardiology	1985-1990

CLINICAL AND RESEARCH POSITIONS:

Assistant Professor, Internal Medicine, University Hospital, Padova, Italy	1990-2005
Associate Professor, Internal Medicine, University of Padova, Italy	2005-2019
Director School of Specialization in Geriatrics, University of Padova, Italy	2014-2018
Associate Professor, Internal Medicine, University of Verona, Italy	2019-pres
Director, Liver Unit, University Hospital, Verona, Italy	2019-pres
N.A.T.O. Research Fellow, Dept. of Pharmacology, New York Medical College, Valhalla, N.Y., U.S.A.	1985
Fogarty International Research Fellow, Dept. Of Pharmacology, New York Medical College, Valhalla, N.Y., U.S.A.	1985-1986
Adjunct Assistant Professor, Dept. Of Pharmacology, New York Medical College, Valhalla, N.Y., U.S.A.	1988-pres

AWARDS:

N.A.T.O. Fellowship	1985
Fogarty Fellowship	1985-1986

SUMMARY OF RESEARCH INTERESTS

Portal hypertension. Hemodynamic alterations of cirrhosis and pharmacodynamics. Liver vascular diseases. Doppler-sonography of the liver and the splanchnic circulation. Diabetes. Hypertension. The heme-oxygenase/carbon monoxide system in hypertension and liver pathophysiology. Cytochrome P450-dependent arachidonic acid metabolites in hypertension and liver pathophysiology. Non-alcoholic fatty liver disease (NAFLD) and NASH. Hepatocellular carcinoma (HCC).

PUBLICATIONS:

171 papers published in Journals cited by PubMed (Science, Journal of Clinical Investigation, Lancet, Gastroenterology, Hepatology, Am J of Physiology, J Hepatology, Diabetes, American Heart Journal, Archives of Internal Medicine, Hypertension etc).

Impact Factor: 1538; H-index: 45

Editorial Board:

Associate Editor, Frontiers in Gastrointestinal and Hepatic Pharmacology
Associate Editor, Frontiers in Inflammation Pharmacology
Editorial Board: J. Ultrasound

Verona, 7/2/2025

- 1) Renal haemodynamics in essential hypertension assessed by 133-Xenon washout and selective renal angiography.
Gatta A., Merkel C., Pessina A.C., Milani L., Sacerdoti D., Zuin R.
Angiology 1982;33:818-824.
- 2) Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension.
Gatta A., Sacerdoti D., Merkel C., Milani L., Battaglia G., Zuin R.
Am Heart J 1984;108:1167-1172.
- 3) Blood flow of experimental liver metastases in rat as evaluated by the locally injected 133-Xenon washout.
Merkel C., Cagol P.P., Da Pian P.P., Bolognesi M., Sacerdoti D., Gatta A.
Res Exp Med 1985;185:207-215.
- 4) Use of a non-selective beta-blocker, nadolol, in the treatment of portal hypertension in cirrhotics.
Gatta A., Sacerdoti D., Merkel C., Rossoni R., Finucci G., Bolognesi M., Zuin R.
Int J Clin Pharmacol Res 1985;5:413-418.
- 5) Redistribution of renal blood flow in patients with liver cirrhosis: the role of renal PGE2.
Sacerdoti D., Merlo A., Merkel C., Zuin R., Gatta A.
J Hepatol 1986;2:253-261.
- 6) Effect of nadolol on liver haemodynamics and function in patients with cirrhosis.
Merkel C., Sacerdoti D., Finucci G.F., Zuin R., Bazzlerla G., Bolognesi M., Gatta A.
Br J Clin Pharmacol 21:713-719,1986. (IF 2.681)
- 7) Nadolol for prevention of variceal rebleeding in cirrhosis: a controlled clinical trial.
Gatta A., Merkel C., Sacerdoti D., Bolognesi M., Caregaro L., Zuin R., Angeli P., Ruol A.
Digestion 37:22-28,1987. (IF 2.097)
- 8) Renal effects of nadolol in cirrhosis.
Gatta A., Sacerdoti D., Merkel C., Caregaro L., Borsato M., Bolognesi M., Ruol A.
Eur J Clin Pharmacol 33:473-477,1987. (IF 2.177)
- 9) Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis.
Merkel C., Finucci G.F., Zuin R., Bazzlerla G., Bolognesi M., Sacerdoti D., Gatta A.
J Hepatol 4:174-180,1987. (IF 6.642)
- 10) Long-term effects of beta-adrenergic blockade with nadolol on hepatic and renal haemodynamics and function in cirrhotics.
Gatta A., Bolognesi M., Merkel C., Finucci G.F., Sacerdoti D., Ruol A.
Clin Physiol 7:371-381,1987. (IF 1.000)
- 11) Effect of somatostatin on liver blood flow and liver metabolic activity in patients with cirrhosis.
Merkel C., Gatta A., Caregaro L., Sacerdoti D., Rondana M., Ruol A.
Scand J Clin Lab Invest 47:667-672,1987. (IF 1.235)
- 12) Semiquantitative angiographic assessment of portal perfusion in cirrhotic patients: relation to hepatic plasma flow.
Finucci G.F., Merkel C., Tirelli M., Sacerdoti D., Gatta A., Zuin R.
Gastroenterol Clin Biol 11:833-834,1987. (IF 0,846)
- 13) Long-term effects of nadolol on quantitative liver function tests in patients with cirrhosis.
Merkel C., Gatta A., Sacerdoti D., Bolognesi M., Rondana M., Caregaro L., Finucci G.F., Ruol A.
Eur J Clin Pharmacol 34:501-504,1988. (IF 2,177)
- 14) Renal cytochrome P450-dependent metabolism of arachidonic acid (AA) in spontaneously hypertensive rats (SHR).
Sacerdoti D., Abraham N.G., McGiff J.C., Schwartzman M.L.
Biochem Pharmacol 37:521-527,1988. (IF 4.006)
- 15) Novel renal arachidonate metabolites.
Carroll M.A., Schwartzman M.L., Sacerdoti D., McGiff J.C.
Am J Med Sci 1988;295:268-274.,
- 16) Systemic hemodynamics in cirrhotic patients: relationships with plasma levels and pulmonary exchange of PGE2.

Merlo A., Amodio P., Sacerdoti D., Borsato M., Merkel C., Angeli P., Gatta A.
Ann Ital Med Int 3:186-189,1988.

17) Effects of Iloprost, a prostacyclin analog derivative, on renal plasma flow, renal function and renin-aldosterone system in man.

Angeli P., Gatta A., Caregaro L. Menon F., Sacerdoti D., Merkel C., Visona' A., Lusiani L., Pagnan A.
Clin Pharmacol Ther 44:211-216,1988.

18) Differential effects of partial hepatectomy on hepatic and renal heme and cytochrome P450 metabolism.

Solangi K., Sacerdoti D., Goodman A.I., Schwartzman M.L., Abraham N.G.
Am J Med Sci 296:387-391,1988.

19) The renal cytochrome P450 system generates novel arachidonic acid metabolites.
Schwartzman M.L., Carroll M.A., Sacerdoti D., Abraham N.G., McGiff J.C.
Adv Exp Med Biol 259:109-129,1989.

20) Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats.

Sacerdoti D., Escalante B., Abraham N.G., McGiff J.C., Levere R.D., Schwartzman M.L.
Science 243:388-390,1989.

21) Prognostic indicators of survival in patients with cirrhosis and esophageal varices, without previous bleeding.

Merkel C., Bolognesi M., Angeli P., Noventa F., Caregaro L., Sacerdoti D., Gatta A.
Am J Gastroenterol 84:717-722,1989.

22) Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance.
Angeli P., Gatta A., Caregaro L., Menon F., Sacerdoti D., Merkel C., Rondana M., De Toni R., Ruol A.
Eur J Clin Invest 20:111-117,1990.

23) Impaired renal response to a meat meal in insulin-dependent diabetes: role of glucagon and prostaglandins.

Fioretto P., Trevisan R., Valerio A., Avogaro A., Borsato M., Doria A., Semplicini A., Sacerdoti D., Jones S., Bognetti E., Viberti G.C., Nosadini R.
Am J Physiol 1990;258:F675-F683.

24) Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins.
Kontessis P., Jones S., Dodds R., Trevisan R., Nosadini R., Fioretto P., Borsato M., Sacerdoti D., Viberti G.C.
Kidney Int 38:136-144,1990.

25) Effects of defibrotide on renal function and urinary prostanoïd excretion in cyclosporin-treated rats.

Rigotti P., Amodio P., Sacerdoti D., Ferrarese M., Borsato M., Morpurgo E., Menon F., Angeli P.
Nephron 59:477-481,1991.

26) Increased renal production of cytochrome P450-dependent metabolites of arachidonic acid in cyclosporine-induced nephrotoxicity.

Sacerdoti D., Borsato M., Rigotti P., Amodio P., Angeli P., Ferrarese M., Plebani M., Gatta A.
Adv Prostaglandin Thromboxane Leukot Res 21:689-692,1991.

27) Importance of 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis.

Sacerdoti D., Merkel C., Gatta A.
J Hepatol 12:124-125,1991.

28) Renal cytochrome P450-dependent metabolism of arachidonic acid in cirrhotic rats.
Sacerdoti D., Escalante B., Schwartzman M.L., Gatta A., McGiff J.C.

J Hepatol 12:230-235,1991.

29) Comparison of sublingual Captopril and Nifedipine in acute treatment of hypertensive emergencies: a randomized one blind trial.

Angeli P., Chiesa M., Caregaro L., Merkel C., Sacerdoti D., Rondana M., Gatta A.
Arch Int Med 151:678-682,1991.

30) Chronic treatment with tin normalizes blood pressure in spontaneously hypertensive rats.
 Escalante B., Sacerdoti D., Davidian M.M., Schwartzman M.L., McGiff J.C.
Hypertension 17:776-779,1991.

31) A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in non-azotemic cirrhotics.
 Gatta A., Angeli P., Caregaro L., Menon F., Sacerdoti D., Merkel C.
Hepatology 14:231-236,1991.

32) Impaired response to angiotensin II in type 1 (insulin-dependent) diabetes mellitus. Role of prostaglandins and sodium-lithium countertransport activity.
 Fioretto P., Sambataro M., Cipollina M.G., Duner E., Morocutti A., Mollo F., Ben G.P., Carraro A., Sacerdoti D., Brocco E., Opocher G., Nosadini R.
Diabetologia 34:595-603,1991

33) Effect of acute and chronic treatment of tin on blood pressure in spontaneously hypertensive rats.
 Laniado-Schwartzman M., Abraham N.G., Sacerdoti D., Escalante B., McGiff J.C.
Tohoku J Exp Med 166:85-91,1992

34) Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices.
 Merkel C., Bolognesi M., Bellon S., Zuin R., Finucci G.F., Noventa F., Sacerdoti D., Angeli P., Gatta A.
Gastroenterology 102:973-979,1992.

35) Long-term follow-up study of adult patients with non-cirrhotic obstruction of the portal system: comparison with cirrhotic patients.
 Merkel C., Bolognesi M., Bellon S., Sacerdoti D., Bianco S., Amodio P., Gatta A.
J Hepatol 15:299-303,1992.

36) Role of atrial natriuretic peptide in the pathogenesis of sodium retention in IDDM with and without glomerular hyperfiltration.
 Fioretto P., Sambataro M., Cipollina M.R., Giorato C., Carraro A., Opocher G., Sacerdoti D., Brocco E., Morocutti A., Mantero F., Gatta A., Nosadini R.
Diabetes 41:936-945,1992.

37) Effect of triglycyl-lysin-vasopressin on quantitative liver function tests in patients with cirrhosis.
 Merkel C., Bianco S., Bolognesi M., Caregaro L., Amodio P., Sacerdoti D., Gatta A.
Amer J Gastroenterol 87:1580-6,1992.

38) The renin-angiotensin system in cirrhosis without ascites. Relationships to renal and intrarenal hemodynamics and portal pressure.
 Sacerdoti D., Merkel C., De Toni R., Finucci G.F., Gatta A.
Eur J Intern Med 2:229-234,1992.

39) Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics: pathophysiological and clinical implications.
 Angeli P., Caregaro L., Menon F., Sacerdoti D., De Toni R., Merkel C., Gatta A.
Hepatology 16:1389-1394,1992.

40) Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography.
 Sacerdoti D., Bolognesi M., Merkel C., Angeli P., Gatta A.
Hepatology 17:219-224,1993.

41) Cardiac involvement in liver cirrhosis.
 Gatta A., Merkel C., Sacerdoti D., Angeli P.
Ann Ital Med Int 8(4):244-7,1993.

42) Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis.
 Bolognesi M., Merkel C., Bianco S., Angeli P., Sacerdoti D., Amodio P., Gatta A.
Hepatology 19:628-634,1994.

43) Pre-and postoperative evaluation of vascular resistance in living related renal allografts under cyclosporine infusion.
 Rigotti P., Sacerdoti D., Bolognesi M., Bombonato G.C., Capalbo M., Di Landro D., Antonello A., Nolli M.L., Gatta A., Ancona E.

44) Duplex Doppler sonographic evaluation of splanchnic and renal effects of single agent and combined therapy with nadolol and Isosorbide-5-Mononitrate in cirrhotic patients.
Bolognesi M., Sacerdoti D., Merkel C., Gatta A.
J Ultrasound Med 13:945-952,1994.

45) Renal vasoconstriction in cirrhosis. Reply.
Sacerdoti D., Bolognesi M., Merkel C., Angeli P., Gatta A.
Hepatology 20:539-541,1994.

46) Inter-observer and inter-equipment variability of echo-Doppler examination of the portal vein: effect of a cooperative training program.
Sabbà C., Merkel C., Zoli M., Ferraioli G., Gaiani S., Sacerdoti D., Bolondi L.
Hepatology, 21:428-433,1995.

47) Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: Relationships with portal hemodynamics.
Sacerdoti D., Merkel C., Bolognesi M., Amodio P., Angeli P., Gatta A.
Gastroenterology 108:1152-1158,1995.

48) Relationship between portal blood flow measured by duplex Doppler ultrasound and hepatic blood flow measured by indocyanine green constant infusion in patients with cirrhosis.
Bolognesi M., Sacerdoti D., Merkel C., Gatta A.
J Clin Ultrasound 23:297-303,1995.

49) Paraumbilical vein patency in cirrhosis: effects on hepatic hemodynamics evaluated by Doppler sonography.
Sacerdoti D., Bolognesi M., Bombonato GC., Gatta A.
Hepatology 22:1689-1694,1995.

50) Duplex Doppler ultrasonography allows a multi-organ non-invasive approach to splanchnic pharmacodynamics in patients with cirrhosis.
Bolognesi M., Sacerdoti D., Merkel C., Caregaro L., Bellon S., Gatta A.
Bildgebung, 62:138-143,1995.

51) Optimizing the time-frame for the definition of bleeding-related death after acute variceal bleeding in cirrhosis.
Merkel C., Gatta A., Bellumat A., Bolognesi M., Borsato L., Caregaro L., Cavallarin G., Cielo R., Cristina P., Cucci E., Donada C., Donadon V., Enzo E., Marin R., Mazzaro C., Sacerdoti D., Torboli P. and the Gruppo Triveneto per l'Ipertensione Portale.
Eur J Gastroenterol Hepatol 8:75-79,1997.

52) Interobserver and inter-equipment variability of echo-Doppler sonographic evaluation of the superior mesenteric artery.
Zoli M., Merkel C., Sabbà C., Sacerdoti D., Gaiani S., Ferraioli G., Bolondi L.
J Ultrasound Med 15:99-106,1996.

53) Left ventricular diastolic function in liver cirrhosis.
Finucci G., Desideri A., Sacerdoti D., Bolognesi M., Merkel C., Angeli P., Gatta A.
Scand J Gastroenterol 31:279-284,1996.

54) The hemodynamic abnormalities in short-term insulin deficiency. The role of prostaglandin inhibition.
Avogaro A., Crepaldi C., Piarulli F., Milan D., Valerio A., Pavan P., Sacerdoti D., Calabro A., Macdonald I., Crepaldi G., Scognamiglio R., Tiengo A.
Diabetes 45:602-609,1996.

55) Splenic Doppler impedance indices: influence of different portal hemodynamic conditions.
Bolognesi M., Sacerdoti D., Merkel C., Gerunda G., Maffei-Faccioli A., Angeli P., Jemmolo R.M., Bombonato G.C., Gatta A.
Hepatology 23:1035-1040,1996.

56) The course of galactose elimination capacity in patients with alcoholic cirrhosis: possible use as a surrogate marker for death.
Merkel C., Marchesini G., Fabbri A., Bianco S., Bianchi G., Enzo E., Sacerdoti D., Zoli M., Gatta A.
Hepatology 1996;24:820-823.

57) Physiopathologic basis of medical therapy of portal hypertension in cirrhosis.
 Gatta A., Bolognesi M., Sacerdoti D., Merkel C.
Ann Ital Med Int 1996;11(suppl 2):39S-47S.

58) Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis.
 Merkel C., Marin R., Enzo E., Donada C., Cavallarin G., Torboli P., Amodio P., Sebastianelli G., Sacerdoti D., Felder M., Mazzaro C., Beltrame P., Gatta A.
Lancet 1996;348:1677-81.

59) Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: comparison between acute and chronic effects.
 Bolognesi M., Sacerdoti D., Merkel C., Bombonato G.C., Enzo E., Gatta A.
J Hepatol 1997;26:305-311.

60) Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone.
 Merkel C., Sacerdoti D., Bolognesi M., Enzo E., Marin R., Bombonato G.C., Angeli P., Gatta A.
Hepatology 1997;26:34-39.

61) Eicosanoid excretion in hepatic cirrhosis: predominance of 20-HETE.
 Sacerdoti D., Balazy M., Angeli P., Gatta A., McGiff J.C.
J Clin Invest 1997;100:1264-1270.

62) Interobserver and interequipment variability of hepatic, splenic, and renal arterial Doppler resistance indices in normal subjects and patients with cirrhosis.
 Sacerdoti D., Gaiani S., Buonamico P., Merkel C., Zoli M., Bolondi L.
J Hepatol 1997;27:986-992.

63) Splenic impedance indices: a useful method to monitor patients after liver transplantation?
 Bolognesi M., Sacerdoti D., Bombonato G.C., Angeli P., Gerunda G., Merenda R., Volpin R., Iemollo R.M., Gatta A.
Hepatology 1998;27:674-678.

64) Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment.
 Merkel C., Sacerdoti D., Bolognesi M., Bombonato G.C., Gatta A.
J Hepatol 1998;28:622-630.

65) Q-T interval prolongation in liver cirrhosis: reversibility after orthotopic liver transplantation.
 Finucci G., Lunardi F., Sacerdoti D., Volpin R., Bortoluzzi A., Bombonato G.C., Angeli P., Gatta A.
Jpn Heart J 1998;39:321-329.

66) Updating prognosis of cirrhosis by Cox's regression model using Child-Pugh score and aminopyrine breath test as time-dependent covariates.
 Merkel C., Morabito A., Sacerdoti D., Bolognesi M., Angeli P., Gatta A.
Ital J Gastroenterol Hepatol 1998;30:276-282.

67) Portal hypertension: state of the art.
 Gatta A., Sacerdoti D., Bolognesi M., Merkel C.
Ital J Gastroenterol Hepatol 1999;31(4):326-45.

68) Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis.
 Merkel C., Sacerdoti D., Bolognesi M., Buonamico P., Sticca A., Amodio P., Angeli P., Micotti L., Gatta A.
Eur J Gastroenterol Hepatol 1999;11:1221-5.

69) Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis.
 Merkel C., Marin R., Sacerdoti D., Donada C., Cavallarin G., Torboli P., Amodio P., Sebastianelli G., Bolognesi M., Felder M., Mazzaro C., Gatta A.
Hepatology 31:324-329,2000. (IF 10.734)

70) Arterioportal fistulas in patients with liver cirrhosis: Usefulness of echo-color-Doppler for screening.
 Bolognesi M., Sacerdoti D., Bombonato G.C., Chiesura-Corona M., Merkel C., Gatta A.
Radiology 2000;216:738-743.

71) The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis.
 Merkel C., Bolognesi M., Sacerdoti D., Bombonato G.C., Bellini B., Bighin R., Gatta A.
Hepatology 2000;32:930-4.

72) Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index.
 Merkel C., Zoli M., Siringo S., van Buuren H., Magalotti D., Angeli P., Sacerdoti D., Bolondi L., Gatta A.
Am J Gastroenterol 2000;95:2915-20.

73) Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients.
 Avogaro A., Miola M., Favaro A., Gottardo L., Pacini G., Manzato E., Zambon S., Sacerdoti D., de Kreutzenberg S., Piliego T., Tiengo A., Del Prato S.
Eur J Clin Invest 2001;31:603-609.

74) Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler
 Bolognesi M., Sacerdoti D., Merkel C., Bombonato G.C., Gatta A.
Ultrasound Med Biol 2001;27:901-907.

75) Change in portal flow after liver transplantation: effect of hepatic arterial resistance indices and role of spleen size.
 Bolognesi M., Sacerdoti D., Bombonato G.C., Merkel C., Sartori G., Merenda R., Nava V., Angeli P., Feltracco P., Gatta A.
Hepatology 2002;35:601-608.

76) Arteroportal fistulas between the accessory right hepatic, gastroduodenal and superior mesenteric arteries and portal vein: a difficult technical problem to overcome in liver transplantation.
 Gerunda G.E., Merenda R., Neri D., Barbazza F., Angeli P., Sacerdoti D., Miotto D., Valmasoni M., Zangrandi F., Gangemi A., Faccioli A.M.
Transplantation 2002;15;73(3):417-9.

77) Role of spleen enlargement in cirrhosis with portal hypertension.
 Bolognesi M., Merkel C., Sacerdoti D., Nava V., Gatta A.
Digest Liver Dis 2002;34:144-50.

78) Nitric oxide modulation of renal and cardiac hemodynamics in type 2 diabetes.
 Dalla Vestra M., Sacerdoti D., Bombonato G.C., Fioretto P., Finucci G.F., Saller A., Sfriso A., Bruseghin M., Sambataro M., Velussi M., Baggio B., Nosadini R., Crepaldi G.
Eur J Endocrinol 2002;146:687-694.

79) Central nervous system alterations in liver cirrhosis: the role of portal-systemic shunt and portal hypertension.
 Del Piccolo F., Sacerdoti D., Amodio P., Bombonato G.C., Bolognesi M., Mapelli D., Gatta A.
Metab Brain Dis 2003;18:51-62.

80) Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.
 Sacerdoti D., Gatta A., McGiff J.C.
Prostaglandins Other Lipid Mediat 72:51-71,2003. (IF 1.968)

81) Alterations in thyroid Doppler arterial resistance indices, volume and hormones in cirrhosis: relationships with splanchnic haemodynamics.
 Spadaro L., Bolognesi M., Pierobon A., Bombonato G.C., Gatta A., Sacerdoti D.
Ultrasound Med Biol 2004;30:19-25.

82) Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats.
 Sacerdoti D., Abraham N.G., Oyekan A.O., Yang L., Gatta A., McGiff J.C.
J Pharmacol Exp Ther 2004;308:636-643, 2004.

83) Identification of 5,6-trans-epoxyeicosatrienoic acid in the phospholipids of red blood cells.
 Jiang H., McGiff J.C., Quillay J., Sacerdoti D., Reddy L.M., Falck J.R., Zhang F., Lerea K.M., Wong P.Y.
J Biol Chem 2004;27;279(35):36412-8.

84) Acute liver rejection: accuracy and predictive values of doppler US measurements--initial

experience.

Bolognesi M., Sacerdoti D., Mescoli C., Nava V., Bombonato GC., Merkel C., Merenda R., Angeli P., Rugge M., Gatta A.
Radiology 2005;235:651-658.

85) Carbon monoxide signaling in promoting angiogenesis in human microvessel endothelial cells.

Li Volti G., Sacerdoti D., Sangras B., Vanella A., Alexandre M., Scapagnini G., Falck J.R., Abraham N.G.
Antioxid Redox Signal 2005;7:704-710.

86) Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation.

Merkel C., Bolognesi M., Sacerdoti D., Bombonato G., Cavasin L., Gatta A.
Aliment Pharmacol Ther. 2005;22(5):433-9.

87) Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites.

Bolognesi M., Sacerdoti D., Di Pascoli M., Angeli P., Quarta S., Sticca A., Pontisso P., Merkel C., Gatta A.
Gut 2005;54:1630-1636.

88) Heme oxygenase overexpression attenuates glucose-mediated oxidative stress in quiescent cell phase: linking heme to hyperglycemia complications.

Sacerdoti D., Olszanecki R., Li Volti G., Colombrita C., Scapagnini G., Abraham N.G.
Curr Neurovasc Res 2005;2:103-111,

89) Heme oxygenase-1 transduction in endothelial cells causes downregulation of monocyte chemoattractant protein-1 and of genes involved in inflammation and growth.

Sacerdoti D., Colombrita C., Ghattas MH, Ismaeil EF, Scapagnini G., Bolognesi M., Li Volti G., Abraham NG
Cell Mol Biol 51:363-70, 2005.

90) Chronic CO levels have a beneficial effect on vascular relaxation in diabetes.

Di Pascoli M., Rodella L., Sacerdoti D., Bolognesi M., Turkseven S., Abraham N.G.
Biochem Biophys Res Commun. 340(3):935-943,2006.

91) Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid (EET) is mediated by activating heme oxygenase (HO)

Sacerdoti D., Bolognesi M., Di Pascoli M., Gatta A., McGiff J.C., Schwartzman M.L., Abraham N.G.
Am J Physiol Heart Circ Physiol 291(4):H1999-2002,2006.

92) Effect of potassium canrenoate, an antialdosteronic agent, on incidence of ascites and variceal progression in cirrhosis.

Bolondi L., Piscaglia F., Gatta A., Salerno F., Bernardi M., Ascione A., Ferràù O., Sacerdoti D., Visentin S., Trevisani F., Mazzanti R., Donati G., Arena U., Gentilini P. DOC (Decrease Of Complications in cirrhosis) Study Group.
Clin Gastroenterol Hepatol 2006;4(11):1395-402.

93) The safety of Sonovue in abdominal applications: retrospective analysis of 23.188 investigations.

Piscaglia F., Bolondi L.; Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents.
Ultrasound Med Biol 2006; 32(9):1369-75.

94) 11,12-epoxyeicosatrienoic acid (11,12-EET) stimulates heme-oxygenase-1 (HO-1) in endothelial cells.

Sacerdoti D., Colombrita C., Di Pascoli M., Schwartzman M.L., Bolognesi M., Falck J.R., Gatta A., Abraham N.G.
Prostaglandins Other Lipid Mediat 2007; 82:155-161.

95) Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters.

Bolognesi M., Sacerdoti D., Mescoli C., Bombonato G., Cillo U., Merenda R., Giacomelli L., Merkel C., Rugge M., Gatta A.
Scand J Gastroenterol. 2007 Feb;42(2):256-62.

96) Carbon Monoxide-Mediated Activation of Large-Conductance Calcium-Activated Potassium

Channels (BKCa) Contributes to Mesenteric Vasodilatation in Cirrhotic Rats.
 Bolognesi M, Sacerdoti D., Piva A, Di Pascoli M, Zampieri F, Quarta S, Motterlini R, Angeli P, Merkel C, Gatta A.
J Pharmacol Exp Ther. 2007;321(1):187-94.

97) Thrombosis of the portal venous system.
 Sacerdoti D, Serianni G, Gaiani S, Bolognesi M, Bombonato GC, Gatta A.
J Ultrasound 2007;10:12-21.

98) New abdominal collaterals at ultrasound: A clue of progression of portal hypertension.
 Berzigotti A, Merkel C, Magalotti D, Tiani C, Gaiani S, Sacerdoti D, Zoli M.
Dig Liver Dis. 2008 Jan;40(1):62-7.

99) Hepatitis C virus reinfection in liver transplant patients: Evaluation of liver damage progression with echo-color doppler.
 Bolognesi M, Quaglio C, Bombonato G, Guido M, Cavalletto L, Chemello L, Merkel C, Rugge M, Gatta A, Sacerdoti D.
Liver Transpl 2008;15:616-24.

100) Natural heme oxygenase-1 inducers in hepatobiliary function.
 Li Volti G, Sacerdoti D, Di Giacomo C, Barcellona ML, Scacco A, Murabito P, Biondi A, Basile F, Gazzolo D, Abella R, Frigiola A, Galvano F.
World J Gastroenterol 2008;14:6122-6132.

101) Nonalcoholic fatty liver disease (NAFLD) of non-obese diabetes: prevalence and relationships with Doppler hemodynamic alterations.
 Gaiani S, Avogaro A, Bombonato GC, Bolognesi M, Conte B, Amor F, De Kreuzenberg S, Guarneri G, Sacerdoti D.
J Ultrasound 2009;12:1-5.

102) Heme Oxygenase: The Key to renal function regulation.
 Abraham NG, Cao J, Sacerdoti D, Li X, Drummond GS
Am J Physiol Renal Physiol. 2009 Nov;297(5):F1137-52.

103) Heme oxygenase regulates renal arterial resistance and sodium excretion in cirrhotic rats.
 Di Pascoli M, Zampieri F, Quarta S, Sacerdoti D, Merkel C, Gatta A, Bolognesi M.
J Hepatol. 2010 54(2):258-64.

104) Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats.
 Bolognesi M, Zampieri F, Di Pascoli M, Verardo A, Turato C, Calabrese F, Lunardi F, Pontisso P, Angeli P, Merkel C, Gatta A, Sacerdoti D.
Liver Int. 2011;31(6):881-90.

105) Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee.
 Senzolo M, Riggio O, Primignani M; Italian Association for the Study of the Liver. Collaborators: Marino LB, Crema EB, de Feo T, De Santis A, Fabris FM, Guido M, Maggi U, Martinelli I, Merli M, Nicolini A, Rossi G, Sabbà C, Sacerdoti D, Salerno F, Senzolo M, Vizzutti F.
Dig Liver Dis. 2011;43(7):503-14.

106) 11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertension.
 Sacerdoti D, Jiang H, Gaiani S, McGiff JC, Gatta A, Bolognesi M.
Prostaglandins Other Lipid Mediat. 2011;96:72-75.

107) Splenic Doppler impedance indices estimate splenic congestion in patients with right-sided or congestive heart failure.
 Bolognesi M, Quaglio C, Bombonato G, Gaiani S, Pesce P, Bizzotto P, Favaretto E, Gatta A, Sacerdoti D.
Ultrasound Med Biol. 2012 Jan;38(1):21-7.

108) Role of HO/CO in the Control of Peripheral Circulation in Humans.
 Sacerdoti D, Mania D, Pesce P, Gaiani S, Gatta A, Bolognesi M.
Int J Hypertens. 2012;2012:236180.

109) No association between the degree of liver steatosis and early signs of vasculopathy in T2DM.
 Coracina A, Gaiani S, Cosma A, Pellizzari P, Pizzi C, de Kreuzenberg S, Cecchet D, Sacerdoti D, Tessari P.

110) Increased EETs participate in peripheral endothelial dysfunction of cirrhosis.
Sacerdoti D, Mania D, Jiang H, Pesce P, Gaiani S, Gatta A, Bolognesi M.
Prostaglandins Other Lipid Mediat. 2012 Aug;98(3-4):129-32.

111) Mesenteric arteries responsiveness to acute variations of wall shear stress is impaired in rats with liver cirrhosis.
Piva A, Zampieri F, Di Pascoli M, Gatta A, Sacerdoti D, Bolognesi M.
Scand J Gastroenterol. 2012;8-9:1003-1013.

112) The emerging role of heme oxygenase and its metabolites in the regulation of cardiovascular function
Stec DE, Ishikawa K, Sacerdoti D, Abraham NG.
International journal of hypertension. 2012;2012:1-2

113) Excessive daytime sleepiness and hepatic encephalopathy: it is worth asking.
De Rui M, Schiff S, Aprile D, Angeli P, Bombonato G, Bolognesi M, Sacerdoti D, Gatta A, Merkel C, Amodio P, Montagnese S.
Metabolic brain disease. 2013;28:245-248

114) HO-1 induction improves the type-1 cardiorenal syndrome in mice with impaired angiotensin ii-induced lymphocyte activation.
Monu SR, Pesce P, Sodhi K, Boldrin M, Puri N, Fedorova L, Sacerdoti D, Peterson SJ, Abraham NG, Kappas A.
Hypertension 2013;62:310-316

115) Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy.
Violi F, Davi G, Hiatt W, Lip GY, Corazza GR, Perticone F, Proietti M, Pignatelli P, Vestri AR, Basili S,Sacerdoti D.
J Am Coll Cardiol. 2013;62:2255-59.

116) Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study.
Raparelli V, Proietti M, Buttà C, Di Giosia P, Sirico D, Gobbi P, Corrao S, Davì G, Vestri AR, Perticone F, Corazza GR, Violi F, Basili S.Sacerdoti D.
Intern Emerg Med. 2014 Dec;9(8):861-70.

117) Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy..
Zaglia T, Milan G, Ruhs A, Franzoso M, Bertaggia E, Pianca N, Carpi A, Carullo P, Pesce P, Sacerdoti D, Sarais C, Catalucci D, Krüger M, Mongillo M, Sandri M.
J Clin Invest 2014;124:2410-2424.

118) Covert hepatic encephalopathy: agreement and predictive validity of different indices.
Montagnese S, Balistreri E, ScProiettiiff S, De Rui M, Angeli P, Zanus G, Cillo U, Bombonato G, Bolognesi M, Sacerdoti D, Gatta A, Merkel C, Amodio P.
World J Gastroenterol. 2014 Nov 14;20(42):15756-62.

119) Beyond scoring: a modern histological assessment of chronic hepatitis should include tissue angiogenesis.
Guido M, Pizzi M, Sacerdoti D, Giacomelli L, Rugge M, Bolognesi M.
Gut. 2014 Aug;63(8):1366-7.

120) Characterization of a murine model of cardiorenal syndrome type 1 by high-resolution Doppler sonography.
Pesce P, Cecchetto L, Brocco S, Bolognesi M, Sodhi K, Abraham NG, Sacerdoti D.
J Ultrasound. 2014 Sep 20;18(3):229-35.

121) Relationship between carotid intima-media thickness and non valvular atrial fibrillation type.
Proietti M, Calvieri C, Malatino L, Signorelli S, Corazza GR, Perticone F, Vestri AR, Loffredo L, Davi G, Violi F, Basili S;Sacerdoti D ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) STUDY Investigators.
Atherosclerosis. 2015 Feb;238(2):350-5.

122) Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvasculature in the joints of psoriatic arthritis.
Fiocco U, Stramare R, Coran A, Grisan E, Scagliori E, Caso F, Costa L, Lunardi F, Oliviero F,

Bianchi FC, Scanu A, Martini V, Boso D, Beltrame V, Vezzù M, Cozzi L, Scarpa R, Sacerdoti D, Punzi L, Doria A, Calabrese F, Rubaltelli L.
Clin Rheumatol. 2015 Nov;34(11):1903-12.

123) Clinical and biochemical determinants of the extent of liver steatosis in type 2 diabetes mellitus.
Cosma A, Cecchet D, Gaiani S, Coracina A, Pellizzari P, Pizzi C, Veronese N, Sacerdoti D, Tessari P.
Eur J Gastroenterol Hepatol. 2015 27(12):1386-91.

124) Arachidonic acid metabolites and endothelial dysfunction of portal hypertension.
Sacerdoti D, Pesce P, Di Pascoli M, Brocco S, Cecchetto L, Bolognesi M.
Prostaglandins Other Lipid Mediat. 2015 Jul;120:80-90.

125) Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation.
Proietti M, Marra AM, Tassone EJ,ARAPACIS collaborators Sacerdoti D.
Am J Cardiol. 2015;116(6):877-882. doi:10.1016/j.amjcard.2015.05.060

126) Changes in gene expression of cytochrome P-450 in liver, kidney and aorta of cirrhotic rats.
Di Pascoli M, Turato C, Zampieri F, Verardo A, Pontisso P, Pesce P, Sacerdoti D, Bolognesi M.
Prostaglandins Other Lipid Mediat. 2015 Jul;120:134-8.

127) Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference.
Andriulli A, Tripodi A, Angeli P, Senzolo M, Primignani M, Giannini EG, Riggio O, Colli A, Prati D, Sacerdoti D, Merkel C, Basili S, Ferro D, Villa E, Di Minno G, Caraceni P, Marzoni M, Mannucci PM, Violi F, Piscaglia F, Calvaruso V, De Pietri L, Falcone M, Feltracco P, Grandone E, La Mura V, Licata A, Lucidi C, Maimone S, Marietta M, Morisco F, Napoleone L, Piano S, Raparelli V, Rebulla P, Riberio D, Sartori MT, Scalera A, Schepis F, Siciliano M, Baroni GS, Tufano A, Vitale A, Zuin M.
Dig Liver Dis. 2016 May;48(5):455-67. .

128) EETs and HO-1 cross-talk.
Sacerdoti D, Pesce P, Di Pascoli M, Bolognesi M.
Prostaglandins Other Lipid Mediat. 2016 Sep;125:65-79.

129) Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombosis Events Registry.
Violi F, Corazza RG, Caldwell SH, Perticone F, Gatta A, Angelico M, Farcomeni A, Masotti M, Napoleone L, Vestri A, Raparelli V, Basili S, PRO-LIVER Collaborators Sacerdoti D.
Intern Emerg Med 2016;11(8):1059-1066.

130) Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study.
Violi F, Davi G, Proietti M, Pastori D, Hiatt WR, Corazza GR, Perticone F, Pignatelli P, Farcomeni A, Vestri AR, Lip GY, Basili S; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) STUDY Investigators, Sacerdoti D.
Thromb Haemost. 2016 Apr;115(4):856-63. doi: 10.1160/TH15-07-0612. Epub 2016 Jan 7. PMID: 26740316.

131) Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation.
Di Pascoli M, Zampieri F, Verardo A, Pesce P, Turato C, Angeli P, Sacerdoti D, Bolognesi M.
Hepatology. 2016 Sep;64(3):923-30.

132) Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F(+)/IL-23(+)/CD161(+) CD4(+) T helper cells in psoriatic arthritis joints.
Fiocco U, Stramare R, Martini V, Coran A, Caso F, Costa L, Felicetti M, Rizzo G, Tonietto M, Scanu A, Oliviero F, Raffeiner B, Vezzù M, Lunardi F, Scarpa R, Sacerdoti D, Rubaltelli L, Punzi L, Doria A, Grisan E.
Clin Rheumatol. 2017 Feb;36(2):391-399.

133) Molecular mechanisms leading to splanchnic vasodilation in liver cirrhosis.
Di Pascoli M, Sacerdoti D, Pontisso P, Angeli P, Bolognesi M.
J Vasc Res. 2017;54(2):92-99.

134) Clinical role of non-invasive assessment of portal hypertension.
Bolognesi M, Di Pascoli M, Sacerdoti D.
World J Gastroenterol. 2017 Jan 7;23(1):1-10.

135) Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study.
 Angelico F, Ginanni Corradini S, Pastori D, Fargion S, Fracanzani AL, Angelico M, Bolondi L, Tozzi G, Pujatti PL, Labbadia G, Corazza GR, Averna M, Perticone F, Croce G, Persico M, Bucci T, Baratta F, Polimeni L, Del Ben M, Violi F, Sacerdoti D, LAL-Cirrhosis Collaborative Research Group..
Atherosclerosis 2017 Jul;262:179-184.

136) Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study.
 Basili S, Loffredo L, Pastori D, Proietti M, Farcomeni A, Vestri AR, Pignatelli P, Davì G, Hiatt WR, Lip GY, Corazza GR, Perticone F, Violi F; in collaboration with ARAPACIS Study Investigators (Sacerdoti D. et al.).
Int J Cardiol. 2017 Mar 15;231:143-149.

137) Heme Oxygenase Induction Suppresses Hepatic Hepcidin and Rescues Ferroportin and Ferritin Expression in Obese Mice
 Puri, N., Arefiev, Y., Chao, R., Sacerdoti, D., Chaudry, H., Nichols, A., Srikathanan, K., Nawab, A., Sharma, D., Lakhani, V.H., Klug, R., Sodhi, K., Peterson, S.J (2017)
J Nutr Metab. 2017, art. no. 4964571, .

138) Heterotopic Implantation of Decellularized Pulmonary Artery Homografts In A Rodent Model: Technique Description and Preliminary Report.
 Dedja A, Padalino MA, Della Barbera M, Rasola C, Pesce P, Milan A, Pozzobon M, Sacerdoti D, Thiene G, Stellin G.
J Invest Surg. 2018 Aug;31(4):282-291.

139) Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study. Basili S, Raparelli V, Napoleone L, Talerico G, Corazza GR, Perticone F, Sacerdoti D, Andriulli A, Licata A, Pietrangelo A, Picardi A, Raimondo G, Violi F.
Am J Gastroenterol. 2018 Mar; 113(3):368-375.

140) Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.
 Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, Proietti M, Davì G, Hiatt WR, Lip GYH, Corazza GR, Perticone F, Violi F, Basili S; ARAPACIS Study Collaborators: Sacerdoti D
Intern Emerg Med. 2018 Aug;13(5):651-660.

141) Development of NASH in Obese Mice is Confounded by Adipose Tissue Increase in Inflammatory NOV and Oxidative Stress.
 Sacerdoti D, Singh SP, Schragenheim J, Bellner L, Vanella L, Raffaele M, Meissner A, Grant I, Favero G, Rezzani R, Rodella LF, Bamshad D, Lebovics E, Abraham NG.
Int J Hepatol. 2018 Jul 2:1-14; ID3484107.

142) Prevalence of metabolic syndrome and non-alcoholic fatty liver disease in a cohort of italian patients with spinal-bulbar muscular atrophy.
 Francini-Pesenti F, Querin G, Martini C, Mareso S, Sacerdoti D.
Acta Myol. 2018 Sep 1;37(3):204-209.

143) A Pig Model of Hemivasculär Liver Occlusion for The Study of Ischemia-Reperfusion Injury: Use of an Infrared System for Detecting Ischemic Areas
 Gringeri E, Vadòri M, De Benedictis GM, Gatto M, Stefani A, Di Giunta M, Vitale A, Calabrese F, Sacerdoti D, Cozzi E, Cillo U
Journal of Surgery, 2019;12:1-8.

144) Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis.
 Basili S, Carnevale R, Nocella C, Bartimoccia S, Raparelli V, Talerico G, Stefanini L, Romiti GF, Perticone F, Corazza GR, Piscaglia F, Pietrangelo A, Violi F;...Sacerdoti D PRO-LIVER Collaborators.
Hepatol Commun. 2019 Mar 2;3(4):504-512. doi: 10.1002/hep4.1317.

145) Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients.
 Violi F, Corazza GR, Caldwell SH, Talerico G, Romiti GF, Napoleone L, Perticone F, Bolondi L, Pietrangelo A, Vestri AR, Raparelli V, Basili S,Sacerdoti D PRO-LIVER Collaborative Group.
Thromb Haemost. 2019 Mar;119(3):496-499.

146) Myocardial overexpression of ANKRD1 causes sinus venosus defects and progressive

diastolic dysfunction.

Piroddi N, Pesce P, Scellini B, Manzini S, Ganzetti GS, Badi I, Menegolli M, Cora V, Tiso S, Cinquetti R, Monti L, Chiesa G, Bleyl SB, Busnelli M, Dellera F, Bruno D, Caicci F, Grimaldi A, Taramelli R, Manni L, Sacerdoti D, Tesi C, Poggesi C, Ausoni S, Acquati F, Campione M. *Cardiovasc Res.* 2020 Jul 1;116(8):1458-1472.

147) Hyperdynamic circulatory syndrome in a mouse model transgenic for SerpinB3.

Villano G, Verardo A, Martini A, Brocco S, Pesce P, Novo E, Parola M, Sacerdoti D, Di Pascoli M, Fedrigo M, Castellani C, Angelini A, Pontisso P, Bolognesi M *Ann Hepatol.* 2020 Jan - Feb;19(1):36-43.

148) Comparison of fondaparinux and low molecular weight heparin in the treatment of portal vein thrombosis in cirrhosis.

Senzolo M, Piano S, Shalaby S, Tonon M, Tonello S, Zanetto A, Sacerdoti D, Simioni P, Bombonato G, Burra P, Angeli P.

Am J Med. 2021; 134:1278-1285.e2. doi: 10.1016/j.amjmed.2021.05.013. PMID: 34197784.

149) Platelets in non-alcoholic fatty liver disease.

Dalbeni A, Castelli M, Zoncapè M, Minuz P, Sacerdoti D.

Front Pharm 2022 Feb 18;13:842636. doi: 10.3389/fphar.2022.842636. PMID: 35250588; PMCID: PMC8895200.

150) Effects of direct-acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real-life Italian experience.

Dalbeni A, Villani R, Bevilacqua M, Sacco F, Faccincani D, Cattazzo F, Cavallone F, Mantovani A, Ceruti V, Ieluzzi D, Paon V, Mantovani A, Serviddio G, Sacerdoti D. *J Dig Dis.* 2022; 23:324-330. doi: 10.1111/1751-2980.13103. PMID: 35700113.

151) Subclinical and clinical atherosclerosis in Non-alcoholic Fatty Liver Disease is associated with the presence of hypertension.

Cattazzo F, Lombardi R, Mantovani A, Bevilacqua M, Zoncapè M, Iogna Prat L, Roccarina D, Fortuna L, Cespiati A, Sacerdoti D, Fracanzani AL, Tsochatzis E, Fava C, Dalbeni A. *Nutr Metab Cardiovasc Dis* 2022 32:2839-2847. DOI: [10.1016/j.numecd.2022.08.005](https://doi.org/10.1016/j.numecd.2022.08.005) PMID: 36404479

152) The multi-drug resistant organisms infections decrease during the antimicrobial stewardship era in cirrhotic patients: An Italian cohort study.

Dalbeni A, Mantovani A, Zoncapè M, Cattazzo F, Bevilacqua M, De Marco L, Paon V, Ieluzzi D, Azzini AM, Carrara E, Tacconelli E, Sacerdoti D. *PLoS One.* 2023 Feb 16;18(2):e0281813. doi: 10.1371/journal.pone.0281813. PMID: 36795664; PMCID: PMC9934314.

153) Interleukin-6: A New Marker of Advanced-Sarcopenic HCC Cirrhotic Patients

Dalbeni A, Natola LA, Garbin M, Zoncapè M, Cattazzo F, Mantovani A, Vella A, Canè S, Kassem J, Bevilacqua M, Conci S, Campagnaro T, Ruzzenente A, Auriemma A, Drudi A, Zanoni G, Guglielmi A, Milella M, Sacerdoti D. *Interleukin-6: A New Marker of Advanced-Sarcopenic HCC Cirrhotic Patients.* *Cancers (Basel).* 2023 Apr 22;15(9):2406. doi: 10.3390/cancers15092406. PMID: 37173873; PMCID: PMC10177287.

154) SerpinB3 as hepatic marker of post-resective shear stress.

Gringeri E, Villano G, Brocco S, Polacco M, Calabrese F, Sacerdoti D, Cillo U, Pontisso P. *Updates Surg.* Sep;75(6):1541-1548;2023. doi: 10.1007/s13304-023-01531-6. PMID: 37204659.

155) Spur cells in liver cirrhosis are predictive of acute-on-chronic liver failure and liver-related mortality regardless of severe anaemia.

Bevilacqua M, De Marco L, Stupia R, Dima F, Cattazzo F, Paon V, Ieluzzi D, Dalbeni A, Sacerdoti D.

Intern Emerg Med 18(5):1397-1404;2023 doi: 10.1007/s11739-023-03303-x. Epub ahead of print. PMID: 37212944. .

156) Metabolic-associated fatty liver disease and liver fibrosis scores as COVID-19 outcome predictors: a machine-learning application.

Zoncapè M, Carlin M, Bicego M, Simonetti A, Ceruti V, Mantovani A, Inglese F, Zamboni G, Sartorio A, Minuz P, Romano S, Crisafulli E, Sacerdoti D, Fava C, Dalbeni A. *Intern Emerg Med.* Oct;18(7):2063-2073;2023. doi: 10.1007/s11739-023-03316-6. Epub ahead of print. PMID: 37268769; PMCID: PMC10238243.

157) A Phase IIa active-comparator-controlled study to evaluate the efficacy and safety of

efinopegdutide in patients with non-alcoholic fatty liver disease.
Romero-Gómez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS; MK-6024 P001 Study Group Sacerdoti D. *J Hepatol.* 79:888-897;2023. PMID: 37355043.

158) Bacterial infections as a risk factor for non-neoplastic portal vein thrombosis development in cirrhotic patients.
Dalbeni A, Cattazzo F, De Marco L, Bevilacqua M, Zoncapè M, Lombardi R, Stupia R, Mantovani A, Sacerdoti D. *Dig Liver Dis.* 2023 Sep 29:S1590-8658(23)00957-X. doi: 10.1016/j.dld.2023.09.012. Epub ahead of print. PMID: 37778894.

159) Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant
Mehta G, Riva A, Ballester MP, Uson E, Pujadas M, Carvalho-Gomes Â, Sahuco I, Bono A, D'Amico F, Viganò R, Diago E, Lanseros BT, Inglese E, Vazquez DM, Sharma R, Tsou HLP, Harris N, Broekhoven A, Kikkert M, Morales SPT, Myeni SK, Riveiro-Barciela M, Palom A, Zeni N, Brocca A, Cussigh A, Cmet S, Escudero-García D, Stocco M, Natola LA, Ieluzzi D, Paon V, Sangiovanni A, Farina E, di Benedetto C, Sánchez-Torrijos Y, Lucena-Varela A, Román E, Sánchez E, Sánchez-Aldehuelo R, López-Cardona J, Canas-Perez I, Eastgate C, Jeyanesan D, Morocho AE, Di Cola S, Lapenna L, Zaccherini G, Bongiovanni D, Zanaga P, Sayaf K, Hossain S, Crespo J, Robles-Díaz M, Madejón A, Degroote H, Fernández J, Korenjak M, Verhelst X, García-Samaniego J, Andrade RJ, Iruzubieta P, Wright G, Caraceni P, Merli M, Patel VC, Gander A, Albillas A, Soriano G, Donato MF, Sacerdoti D, Toniutto P, Buti M, Duvoux C, Grossi PA, Berg T, Polak WG, Puoti M, Bosch-Comas A, Belli L, Burra P, Russo FP, Coenraad M, Calleja JL, Perricone G, Berenguer M, Claria J, Moreau R, Arroyo V, Angeli P, Sánchez C, Ampuero J, Piano S, Chokshi S, Jalan R; COBALT Consortium. *Hepatol Commun.* 2023 Oct 18;7(11):e0273. doi: 10.1097/HIC.0000000000000273. PMID: 37870985; PMCID: PMC10586829.

160) Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Dalbeni A, Lombardi R, Henrique M, Zoncapè M, Pennisi G, Petta S, Tateishi R, Keklikiran C, Colecchia A, Sacerdoti D, Mantovani A, Ravaoli F. *Hepatology.* 2024 May 1;79(5):1107-1116. doi: 10.1097/HEP.0000000000000694. Epub 2023 Nov 16. PMID: 37976417.

161) Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population.
Dalbeni A, Garbin M, Zoncapè M, Romeo S, Cattazzo F, Mantovani A, Cespiati A, Fracanzani AL, Tsouchatzis E, Sacerdoti D, Mantovani A, Lombardi R. *Int J Mol Sci.* 2023 Oct 31;24(21):15837. doi: 10.3390/ijms242115837. PMID: 37958820; PMCID: PMC10649990.

162) Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease: a meta-analysis of observational studies.
Stupia R, Lombardi R, Cattazzo F, Zoncapè M, Mantovani A, De Marco L, Mantovani A, Fracanzani AL, Sacerdoti D, Dalbeni A. *J Thromb Thrombolysis.* 2024 Feb;57(2):330-336. doi: 10.1007/s11239-023-02912-9. Epub 2023 Dec 8. PMID: 38066387; PMCID: PMC10869434.

163) Author's Reply: "Bacterial infections predispose to the development of portal vein thrombosis in patients with decompensated cirrhosis".
Dalbeni A, Cattazzo F, De Marco L, Bevilacqua M, Zoncapè M, Lombardi R, Stupia R, Mantovani A, Sacerdoti D. *Dig Liver Dis.* 2024 Feb;56(2):379-380. doi: 10.1016/j.dld.2023.11.026. Epub 2023 Dec 7. PMID: 38065697.

164) Cholestatic HCV Cryoglobulinemia: A New Clinical and Pathological Entity before and after Direct-Acting Antiviral Therapies-A Case-Control Study.
Ammendola S, Romeo S, Cattazzo F, Mantovani A, Ieluzzi D, Paon V, Montagnana M, Pecori S, Tomezzoli A, Dalbeni A, Sacerdoti D. *Int J Mol Sci.* Jan 8;25(2):784.2024 doi: 10.3390/ijms25020784. PMID: 38255857.

165) Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma.
Giannini EG, Pasta A, Pieri G, Plaz Torres MC, Marseglia M, Pelizzaro F, Sangiovanni A, Cabibbo G, Ghittoni G, Di Marco M, Foschi FG, Guarino M, Biasini E, Saitta C, Campani C, Svegliati-Baroni G, Gasbarrini A, Brunetto MR, Magalotti D, Azzaroli F, Mega A, Sacco R,

Nardone G, Sacerdoti D, Masotto A, Vidili G, Bucci L, Vitale A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Liver Int. 2024 Mar 1. doi: 10.1111/liv.15855. Epub ahead of print. PMID: 38426262.

166) Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.

Di Cola S, D'Amico G, Caraceni P, Schepis F, Loredana S, Lampertico P, Toniutto P, Martini S, Maimone S, Colecchia A, Svegliati Barone G, Alessandria C, Aghemo A, Crocè SL, Adinolfi LE, Rendina M, Lapenna L, Pompili E, Zaccherini G, Saltini D, Iavarone M, Tosetti G, Martelletti C, Nassisi V, Ferrarese A, Giovo I, Masetti C, Pugliese N, Campigotto M, Nevola R, Merli M; EpatoSarco Group (Sacerdoti D).

J Hepatol. 2024 May 21:S0168-8278(24)00355-6. doi: 10.1016/j.jhep.2024.05.020. Epub ahead of print. PMID: 38782120.

167) Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.

Celsa C, Cabibbo G, Fulgenzi CAM, Battaglia S, Enea M, Scheiner B, D'Alessio A, Manfredi GF, Stefanini B, Nishida N, Galle PR, Schulze K, Wege H, Ciccia R, Hsu WF, Vivaldi C, Wietharn B, Lin RP, Pirozzi A, Pressiani T, Dalbeni A, Natola LA, Auriemma A, Rigamonti C, Burlone M, Parisi A, Huang YH, Lee PC, Ang C, Marron TU, Pinter M, Cheon J, Phen S, Singal AG, Gampa A, Pillai A, Roehlen N, Thimme R, Vogel A, Soror N, Ulahannan S, Sharma R, Sacerdoti D, Pirisi M, Rimassa L, Lin CY, Saeed A, Masi G, Schönlein M, von Felden J, Kudo M, Cortellini A, Chon HJ, Cammà C, Pinato DJ.

Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001026. Epub ahead of print. PMID: 39028886.

168) Hepatofugal portal flow is highly predictive of acute-on-chronic liver failure: A new hemodynamic patho-physiological hypothesis.

Michele Bevilacqua, Leonardo M, Roberta S, Filippo C, Mirko Z, Veronica P, Donatella I, Andrea D, David Sacerdoti.

Dig Liver Dis. 2024 Jan 27:S1590-8658(24)00208-1. doi: 10.1016/j.dld.2024.01.190. Epub ahead of print. PMID: 38281869.

169) Risk of Portal Vein Thrombosis in Cirrhosis.

Cangemi R, Raparelli V, Talerico G, Basili S, Violì F; PRO-LIVER Collaborators (Sacerdoti D). Hypoalbuminemia and Gastro Hep Adv. 2024 Mar 13;3(5):646-653. doi: 10.1016/j.gastha.2024.03.006. PMID: 39165413; PMCID: PMC11330931.

170) Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study.

Vitale A, Trapani S, Russo FP, Miele L, Svegliati Baroni G, Marchesini G, Burra P, Ottoveggio MS, Romagnoli R, Martini S, De Simone P, Carrai P, Cescon M, Morelli MC, De Carlis L, Belli L, Gruttaduria S, Volpes R, Colledan M, Fagioli S, Di Benedetto F, De Maria N, Rossi G, Caccamo L, Donato F, Vennarecci G, Di Costanzo GG, Vivarelli M, Carraro A, Sacerdoti D, Ettorre GM, Giannelli V, Agnes S, Gasbarrini A, Rossi M, Gianni Corradini S, Mazzaferro V, Bhoori S, Manzia TM, Lenci I, Zamboni F, Mameli L, Baccarani U, Toniutto P, Lupo LG, Tandoi F, Rendina M, Andorno E, Giannini EG, Spada M, Billato I, Marchini A, Romano P, Brancaccio G, D'Amico F, Ricci A, Cardillo M, Cillo U; Associazione Italiana per lo Studio del Fegato (AISF); Società Italiana Trapianti d'Organo (SITO); Centro Nazionale Trapianti (CNT).

JHEP Rep. 2024 Jun 22;6(9):101147. doi: 10.1016/j.jhepr.2024.101147. PMID: 39282226; PMCID: PMC11399673.

171) Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma.

Giannini EG, Pasta A, Plaz Torres MC, Pieri G, Cabibbo G, Sangiovanni A, Piscaglia F, Campani C, Missale G, Vidili G, Ghittoni G, Pelizzaro F, Foschi FG, Morisco F, Santi V, Svegliati-Baroni G, Azzaroli F, Saitta C, Brunetto MR, Sacco R, Ponziani FR, Boninsegna S, Nardone G, Martini A, Mega A, Sacerdoti D, Magalotti D, Vitale A, Bucci L, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Liver Int. 2025 Feb;45(2):e16185. doi: 10.1111/liv.16185. PMID: 39776202; PMCID: PMC11707821.

